{
  "docId": "019de076-4a3e-76ed-83f8-e348223f91d9",
  "docSlug": "c1eecdcf261eded4e99ffa840c30e475",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 60,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "solution",
  "function": "present_solution",
  "density": "sparse",
  "nDataPoints": 2,
  "notes": "Includes a cartoon liver character at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/13",
  "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9",
  "deckJsonHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9.json",
  "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.84,
        "x": 0.08,
        "y": 0.215
      },
      "kind": "diagram",
      "text": "Resolving CAR-T Neurotoxicity",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "797c45b5-4da2-4559-8b86-de5c4da5e2b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.4,
        "y": 0.735
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e0982f8-27d0-41c1-a3a6-ecfc03428aa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.02,
        "y": 0.06
      },
      "kind": "title",
      "text": "ImmixBio Resolves Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffa3694a-5759-4e6f-827c-88c045593c75",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "487c7c7b-2246-4cd2-a814-71952c425de0",
      "evidence": "Central node connected to four peripheral nodes",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 22,
      "from": 11,
      "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Competitive Analysis",
      "beatSlug": "sequoia-pitch-competition",
      "evidence": "Slides 11-22: Various competitive analysis slides",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a",
      "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity",
      "position": 0,
      "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 60,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "50c25ad2-0c48-4213-947d-b362da490be1",
      "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative",
      "position": 1,
      "objective": "Why is Immix Biopharma's N-GENIUS platform important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}